ÂÜÀòÂÒÂ×

Dr Bizzari started his career as Head of the Oncology at the Institut de Recherches Internationales SERVIER. He has held a number of senior executive positions within the pharmaceutical industry, including a number of VP Clinical Oncology roles at Rhone-Poulenc Rorer, Aventis, Sanofi and Celgene. Dr Bizzari has been involved in the development of numerous compounds including anti-angiogenics (VEGF-trap), gene therapy, vaccines and bio-reductive agents. He was instrumental in the clinical development of several anticancer agents including Taxotere, Revlimid, and Vidaza. Dr Bizzari is a member of the Scientific Advisory Board of the French National Cancer Institute (INCA), and a board member of the European Organization of Research and Treatment of Cancer (EORTC). He holds a medical degree from the University of Nice (France) and trained as an oncologist at the Pitie Salpetriere hospital in Paris, the Ontario Cancer Institute in Toronto and the Mac Gill Cancer Centre in Montreal.